258 related articles for article (PubMed ID: 9002755)
1. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
2. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
3. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
5. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
6. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.
Smets LA; Loesberg C; Janssen M; Metwally EA; Huiskamp R
Cancer Res; 1989 Jun; 49(11):2941-4. PubMed ID: 2720653
[TBL] [Abstract][Full Text] [Related]
7. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
8. Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells.
Iavarone A; Lasorella A; Servidei T; Riccardi R; Troncone L; Mastrangelo R
J Nucl Biol Med (1991); 1991; 35(4):186-90. PubMed ID: 1823815
[TBL] [Abstract][Full Text] [Related]
9. Effect of specific activity on cardiac uptake of iodine-123-MIBG.
Farahati J; Bier D; Scheubeck M; Lassmann M; Schelper LF; Grelle I; Hanscheid H; Biko J; Graefe KH; Reiners C
J Nucl Med; 1997 Mar; 38(3):447-51. PubMed ID: 9074536
[TBL] [Abstract][Full Text] [Related]
10. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
11. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
12. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
13. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.
Montaldo PG; Carbone R; Cornaglia Ferraris P; Ponzoni M
Cytotechnology; 1993; 11 Suppl 1():S140-3. PubMed ID: 7763744
[TBL] [Abstract][Full Text] [Related]
15. SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice.
Clerc J; Halpern S; Fourré C; Omri F; Briançon C; Jeusset J; Fragu P
J Nucl Med; 1993 Sep; 34(9):1565-70. PubMed ID: 8355077
[TBL] [Abstract][Full Text] [Related]
16. Sympathomimetic effects of MIBG: comparison with tyramine.
Graefe KH; Bossle F; Wölfel R; Burger A; Souladaki M; Bier D; Dutschka K; Farahati J; Bönisch H
J Nucl Med; 1999 Aug; 40(8):1342-51. PubMed ID: 10450687
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
19. Potential and practical adrenomedullary PET radiopharmaceuticals as an alternative to m-iodobenzylguanidine: m-(omega-[18F]fluoroalkyl)benzylguanidines.
Lee BC; Paik JY; Chi DY; Lee KH; Choe YS
Bioconjug Chem; 2004; 15(1):104-11. PubMed ID: 14733589
[TBL] [Abstract][Full Text] [Related]
20. No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1996; 7(1):102-7. PubMed ID: 8741997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
